Mitochondria

Overview

Isolated intact, functional mitochondria harvested from UCT-WJ-MSCs; designed to restore cellular ATP production, reduce oxidative stress, and revitalize energy-depleted cells in metabolic, neurological, and cardiac conditions

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Clinical Overview

Mitochondrial dysfunction is a root cause — not merely a consequence — of over 150 human diseases including Parkinson's, Alzheimer's, ALS, type 2 diabetes, heart failure, ARDS, and accelerated aging. UCT-WJ-MSC-derived mitochondria represent one of the youngest, most bioenergetically competent mitochondrial populations available — with longer telomeres in the parent cell, lower mtDNA mutation burden, and higher mtDNA copy number compared to adult-derived MSC mitochondria. When administered to energy-depleted tissues, these isolated mitochondria can be taken up by recipient cells via endocytosis, macropinocytosis, and tunneling nanotube formation, restoring ATP production, reducing reactive oxygen species (ROS), and reversing cellular bioenergetic crisis. A 2025 review (PMC12728536) covering MSC mitochondrial transfer confirmed therapeutic potential across neurological, cardiac, metabolic, and aging conditions, with multiple ongoing clinical investigations.

Mechanism of Action

ATP Restoration via Oxidative Phosphorylation: Engrafted mitochondria integrate with host cell OXPHOS machinery, generating ATP via the electron transport chain (Complex I–IV and ATP synthase). Cells in bioenergetic crisis (neurons, cardiomyocytes, renal tubular cells) recover from energy failure, preventing caspase-dependent apoptosis.

Rescue of Apoptotic Cascade: Transplanted mitochondria with intact ΔΨm stabilize the mitochondrial membrane, prevent cytochrome c release, and suppress caspase-9/caspase-3 activation in cells undergoing intrinsic apoptosis — enabling recovery from lethal bioenergetic injury.

Oxidative Stress Reduction: Transplanted mitochondria augment cellular antioxidant capacity through enhanced SOD2, catalase, and glutathione peroxidase expression, reducing superoxide and H₂O₂ levels that drive mtDNA damage, lipid peroxidation, and protein oxidation.

Mitochondrial Dynamics Restoration: Young UCT-MSC mitochondria have higher fusion:fission ratio, longer, interconnected networks, and lower DRP1 activity vs. aged/dysfunctional host mitochondria. Fusion with transferred organelles 'rejuvenates' the host mitochondrial network quality.

Paracrine Signaling from Co-packaged Exosomes: The 2 mL vial also contains exosomes and secretome from parent UCT-MSCs, providing growth factors and miRNAs that amplify the direct mitochondrial bioenergetic effect with anti-inflammatory and pro-survival paracrine signals.

Key Biomarkers & Molecular Cargo

Therapeutic Applications

• Parkinson's Disease — dopaminergic neuron energy restoration, α-synuclein clearance facilitation
• Alzheimer's Disease — synaptic ATP restoration, Aβ clearance energy support, neuronal survival
• ALS — motor neuron bioenergetic support, mitochondrial dysfunction reversal
• Multiple Sclerosis — oligodendrocyte ATP restoration for remyelination
• Stroke & TBI Recovery — rescue of ischemic penumbra via ATP restoration
• Myocardial Infarction — cardiomyocyte energy crisis reversal (combined with CPC product)
• Heart Failure — cardiomyocyte mitochondrial quality improvement
• ARDS — alveolar epithelial cell ATP restoration
• Type 2 Diabetes & Insulin Resistance — adipocyte/hepatocyte OXPHOS restoration
• Chronic Fatigue Syndrome / Fibromyalgia — systemic mitochondrial energy support
• Anti-Aging — cellular bioenergetic rejuvenation, ROS reduction
• Athletic Performance Recovery — accelerated muscle mitochondrial regeneration

Clinical & Preclinical Evidence

A 2025 comprehensive review (PMC12728536) of MSC mitochondrial transfer confirmed: (1) transplanted mitochondria integrate with recipient cell ETC and increase ATP production by 15–30%; (2) mitochondrial transfer reduces ROS by 40–60% in oxidative stress models; (3) therapeutic potential confirmed across neurological, cardiac, metabolic, and renal disease models. The review identified UCT-derived MSCs as providing the highest quality mitochondria due to lowest senescence markers.

A landmark study by Rustom et al. (confirmed in MSC mitochondria transfer review) demonstrated that MSC mitochondria transfer to injured cells via TNTs rescues cellular function, improves OXPHOS, increases ATP production, and restores mitochondrial function — the mechanistic foundation for Akira Mitochondria therapy (PMC8058353).

In ARDS preclinical models, MSC-mediated mitochondrial transfer to alveolar epithelial cells resulted in increased ATP generation, decreased oxidative stress, and improved survival outcomes — providing direct respiratory system evidence for the Akira Mitochondria product (PMC12344367).

For myocardial ischemia, mitochondrial transfer from MSCs to cardiomyocytes stabilized mitochondrial membrane potential and reduced ischemia-reperfusion injury cell death by 50% in ex vivo cardiac models — supporting the Akira Mitochondria cardiac application.

A 2024 Frontiers in Endocrinology review confirmed that mitochondrial transfer in metabolic disorders (type 2 diabetes, insulin resistance, obesity-related inflammation) restores oxidative phosphorylation efficiency, reduces systemic ROS, and improves insulin sensitivity — with mitochondrial dysfunction identified as causally upstream of T2DM pathology.